Vallon Pharmaceuticals, Inc. [GRI]

Source: 

Company Overview

Vallon Pharmaceuticals, Inc primarily focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. Our lead investigational product candidate, ADAIR, was a proprietary, abuse-deterrent oral formulation of immediate-release dextroamphetamine which was being developed for the treatment of attention-deficit/hyperactivity disorder and narcolepsy.